Post-earnings recap
Reported
Wed, Nov 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by nearly 2% following the announcement, likely due to management's positive outlook on their clinical trials. Investors may be encouraged by the company's ongoing efforts in drug development despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -8.06% |
| Revenue | N/A | N/A | N/A |
Overall, management remains focused on their clinical development efforts. They acknowledged the EPS results but expressed confidence in their long-term strategy.
Management highlighted ongoing clinical trials and their importance for future growth.
They emphasized a commitment to advancing their pipeline despite the EPS miss.